Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 7:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Modified FOLFOX Clear all
Terminated Phase 1 Interventional

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

NCT06704724
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
PF-07985045, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, Sasanlimab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, PF-07284892
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 17, 2026, 7:08 PM EDT
Terminated Phase 1 Interventional

A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

NCT05346484
View directory record Official record
Conditions
Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Cholangiocarcinoma, Bile Duct Cancer
Interventions
CF33-hNIS, Pembrolizumab, Modified FOLFOX
Biological · Drug
Lead sponsor
Imugene Limited
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Springdale, Arkansas • Duarte, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 17, 2026, 7:08 PM EDT
Active, not recruiting Early Phase 1 Interventional

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

NCT05108428
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Capecitabine, Radiation Therapy, FOLFOX regimen
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 17, 2026, 7:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

NCT03611556
View directory record Official record
Conditions
Carcinoma, Metastatic Pancreatic Adenocarcinoma
Interventions
Oleclumab, Durvalumab, Gemcitabine, Nab-paclitaxel, Oxaliplatin, Folinic acid, 5-FU
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
18
States / cities
La Jolla, California • Aurora, Colorado • Fort Myers, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 17, 2026, 7:08 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

NCT05948475
View directory record Official record
Conditions
Cholangiocarcinoma
Interventions
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
Drug
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
19
States / cities
Santa Monica, California • Stanford, California • Westwood, Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 17, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

A Study of Ramucirumab or Icrucumab in Colorectal Cancer

NCT01111604
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Ramucirumab, Icrucumab, mFOLFOX-6
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbia, South Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 17, 2026, 7:08 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer

NCT00463840
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Oxaliplatin, 5FU, Radiation, Surgery, FOLFOX 6
Drug · Radiation · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 17, 2026, 7:08 PM EDT
Completed Phase 1 Interventional Results available

Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors

NCT00599924
View directory record Official record
Conditions
Colorectal Neoplasms, Neoplasms
Interventions
sunitinib + FOLFOX
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Aurora, Colorado • Nashville, Tennessee • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Sep 17, 2026, 7:08 PM EDT
Completed No phase listed Observational

The Inland Northwest Colon Cancer Survivor's Study

NCT01775254
View directory record Official record
Conditions
Colon Cancer
Interventions
Not listed
Lead sponsor
Washington State University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 17, 2026, 7:08 PM EDT
Recruiting Phase 2 Interventional

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

NCT07432295
View directory record Official record
Conditions
Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma
Interventions
Givastomig, Nivolumab, 5Fluorouracil, Leucovorin, Oxaliplatin, Capecitabine
Drug
Lead sponsor
I-Mab Biopharma US Limited
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Goodyear, Arizona • Duarte, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 17, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy

NCT01333033
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Interventions
Oxaliplatin, Leucovorin Calcium, Fluorouracil, Carboplatin, Paclitaxel, Positron Emission Tomography, Computed Tomography, Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
68
States / cities
Mountain View, California • Palo Alto, California • San Francisco, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 17, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia

NCT00591123
View directory record Official record
Conditions
Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus, Unresectable Adenocarcinoma of Gastric Cardia, Metastatic Adenocarcinoma of Gastric Cardia
Interventions
FOLFOX, 5-FU, Erlotinib
Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Sep 17, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets

NCT01581307
View directory record Official record
Conditions
Liver Cancer, Pancreatic Cancer
Interventions
FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin), TheraSpheres
Drug · Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 17, 2026, 7:08 PM EDT
Recruiting Phase 3 Interventional

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

NCT06205485
View directory record Official record
Conditions
Rectal Cancer
Interventions
Leucovorin, Oxaliplatin, Fluoruracil, Capecitabine, Radiation
Drug · Radiation
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
105
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 86 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 17, 2026, 7:08 PM EDT
Terminated Phase 1Phase 2 Interventional

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

NCT02102022
View directory record Official record
Conditions
Advanced Gastrointestinal (GI) Malignancies, Hepatocellular Carcinoma, Gastric Cancer, Colorectal Cancer
Interventions
ADI-PEG 20 plus modified FOLFOX6
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
10
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 17, 2026, 7:08 PM EDT
Active, not recruiting Phase 2 Interventional

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

NCT00335816
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiation therapy, laboratory biomarker analysis, DNA analysis, polymerase chain reaction, immunohistochemistry staining method
Drug · Procedure · Radiation + 2 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
14
States / cities
Concord, California • Duarte, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 17, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer

NCT01666730
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
metformin hydrochloride, oxaliplatin, leucovorin calcium, fluorouracil, laboratory biomarker analysis
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Sep 17, 2026, 7:08 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

NCT07283939
View directory record Official record
Conditions
Ampulla of Vater Carcinoma, Appendix Carcinoma, Carcinoma of Unknown Primary With Gastrointestinal Profile, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Malignant Digestive System Neoplasm, Rectal Carcinoma, Small Intestinal Carcinoma
Interventions
PAGODA algorithm, Oxaliplatin, Folinic Acid, Fluorouracil
Other · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
356
States / cities
Fairbanks, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 266 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 17, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib + mFOLFOX for Hepatocellular Carcinoma

NCT01775501
View directory record Official record
Conditions
Hepatocellular Cancer
Interventions
Leucovorin, Fluorouracil, Oxaliplatin, Sorafenib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Sep 17, 2026, 7:08 PM EDT
Terminated Not applicable Interventional

Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders

NCT03941366
View directory record Official record
Conditions
Rectal Cancer
Interventions
Standard of care chemotherapy with the change for avoidance of extensive surgery
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 95 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 17, 2026, 7:08 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer

NCT00609622
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
sunitinib, mFOLFOX6, bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
81
States / cities
Fairhope, Alabama • Mobile, Alabama • Chandler, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Sep 17, 2026, 7:08 PM EDT
Completed Phase 2 Interventional

A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

NCT00251485
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Cetuximab
Drug
Lead sponsor
Veeda Oncology
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2008 · Synced Sep 17, 2026, 7:08 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer

NCT00625651
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Colon Cancer, Colorectal Cancer, Rectal Cancer
Interventions
Placebo, AMG 655, Modified FOLFOX6, Bevacizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
61
States / cities
Hot Springs, Arkansas • Downey, California • La Jolla, California + 56 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Sep 17, 2026, 7:08 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320
View directory record Official record
Conditions
Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan, 5-fluorouracil, leucovorin, Oxaliplatin
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 17, 2026, 7:08 PM EDT